These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 12364570)

  • 21. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors.
    Yasunaga M; Ohishi Y; Oda Y; Misumi M; Iwasa A; Kurihara S; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
    Hum Pathol; 2009 Jul; 40(7):965-74. PubMed ID: 19269675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors.
    McCluggage WG; Strand K; Abdulkadir A
    Int J Gynecol Cancer; 2002; 12(1):62-5. PubMed ID: 11860537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma.
    Takeuchi T; Ohishi Y; Imamura H; Aman M; Shida K; Kobayashi H; Kato K; Oda Y
    Am J Surg Pathol; 2013 Jul; 37(7):1091-9. PubMed ID: 23681072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade.
    Ahmed N; Pansino F; Clyde R; Murthi P; Quinn MA; Rice GE; Agrez MV; Mok S; Baker MS
    Carcinogenesis; 2002 Feb; 23(2):237-44. PubMed ID: 11872628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
    Grisaru-Granovsky S; Salah Z; Maoz M; Pruss D; Beller U; Bar-Shavit R
    Int J Cancer; 2005 Jan; 113(3):372-8. PubMed ID: 15455382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and correlation of Lewis y antigen and integrins α5 and β1 in ovarian serous and mucinous carcinoma.
    Li Q; Liu S; Lin B; Yan L; Wang Y; Wang C; Zhang S
    Int J Gynecol Cancer; 2010 Dec; 20(9):1482-9. PubMed ID: 21119363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.
    Wang H; Rosen DG; Wang H; Fuller GN; Zhang W; Liu J
    Mod Pathol; 2006 Sep; 19(9):1149-56. PubMed ID: 16729015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fascin in ovarian epithelial tumors.
    Kostopoulou E; Daponte A; Terzis A; Nakou M; Chiotoglou I; Theodosiou D; Chatzichristodoulou C; Messinis IE; Koukoulis G
    Histol Histopathol; 2008 Aug; 23(8):935-44. PubMed ID: 18498068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cytology of ovarian epithelial tumors].
    Otsuki T; Yaegashi N
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():503-6. PubMed ID: 15535296
    [No Abstract]   [Full Text] [Related]  

  • 30. Expression of extracellular matrix proteins in ovarian serous tumors.
    Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
    Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression and significance of basic fibroblast growth factor in ovarian epithelial neoplasm].
    Lin W; Peng ZL
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 1999 Sep; 13(5):299-304. PubMed ID: 12080823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
    Pan Y; Jiao J; Zhou C; Cheng Q; Hu Y; Chen H
    Pathobiology; 2010; 77(6):283-8. PubMed ID: 21266826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and mutational analysis of c-kit in ovarian surface epithelial tumors.
    Kim DJ; Lee MH; Park TI; Bae HI
    J Korean Med Sci; 2006 Feb; 21(1):81-5. PubMed ID: 16479070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DEF6 expression in ovarian carcinoma correlates with poor patient survival.
    Liew PL; Fang CY; Lee YC; Lee YC; Chen CL; Chu JS
    Diagn Pathol; 2016 Aug; 11(1):68. PubMed ID: 27488395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apoptotic and proliferative activity in ovarian benign, borderline and malignant tumors.
    Liu A; Chen L; Ngan HY; Khoo US; Zhao Y; Cheung AN
    Chin Med Sci J; 2002 Jun; 17(2):106-11. PubMed ID: 12906164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
    Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
    Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
    Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
    Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Heterogeneity of epithelial ovarian carcinomas and their clinical significance].
    Noske A
    Praxis (Bern 1994); 2014 Jan; 103(3):155-9. PubMed ID: 24468455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms.
    Litkouhi B; Litkouhi B; Fleming E; Welch WR; Berkowitz RS; Birrer MJ; Mok SC
    Gynecol Oncol; 2008 May; 109(2):234-9. PubMed ID: 18331757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer].
    Shi HR; Zhang RT
    Ai Zheng; 2009 Aug; 28(8):882-5. PubMed ID: 19664338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.